CGuard Brochure References
Wissgott C, Schmidt W, Brandt-Wunderlich et al. Clinical Results and Mechanical Properties of the Carotid CGuard Double-Layered Embolic Prevention Stent. J Endovasc Ther. 2017 Feb;24(1):130-137.

InspireMD's CGuard Prime is a dual-layer, mesh-covered carotid stent whose MicroNet mesh uses non-metallic polyethylene terephthalate for stroke prevention.
inspiremd.comCrawled Nov 14, 2026
Wissgott C, Schmidt W, Brandt-Wunderlich et al. Clinical Results and Mechanical Properties of the Carotid CGuard Double-Layered Embolic Prevention Stent. J Endovasc Ther. 2017 Feb;24(1):130-137.
CGuard Embolic Prevention System is a mesh carotid stent designed for sustained embolic protection, featuring a dual-layer design with a small mesh pore size.
Stroke prevention with CGuard Prime Carotid Stent has been proven in numerous trials and case studies worldwide
The Stent for Life Initiative unites cardiologists, governments, industry, and patients to improve STEMI patient access to life-saving treatments.
The 2023 Fireside Chat Series features discussions on carotid market trends, reimbursement decisions, and patient benefits from experts including Dr. Chris Metzger, Dr. Kenneth Rosenfield, and Dr. Sean Lyden.
Cardiovasc Surg (Torino). 2024;65(3):231-248.
The InspireMD PVI 2025 symposium explores how MicroNet covered carotid stents address embolic protection needs in the post-CREST-2 era.
The MASTER Trial and presentations discuss thrombus management in STEMI using MGuard, with global case studies from Mexico, South Africa, and India.
InspireMD announced the pricing of a public offering for its CGuard Embolic Prevention System, aimed at stroke prevention in carotid artery disease.
InspireMD designs embolic prevention systems for carotid artery stents, prioritizing product quality, patient safety, and clinical effectiveness.
Department: R&D & Engineering Direct Manager (Title): VP R&D, Engineering and Projects Office Location: Israel, Tel Aviv
Department: R&D & EngineeringDirect Manager (Title): VP R&D, Engineering and ProjectsOffice Location: Israel, Tel Aviv A medical device company developing and manufacturing mechanical devices is seeking a talented V&V Engineer to join our R&D and Engineering team. As a V&V Engineer you will work collaboratively with cross-functional team to ensure our medical devices meet all... Read More
InspireMD develops embolic protection systems to prevent stroke and supports stenting as a treatment option for carotid artery intervention.
InspireMD lists U.S. and international patents for its products under 35 USC § 287(a), noting additional patents may exist.
InspireMD provides contact information for inquiries: info@inspiremd.com or 1-888-776-6804.
Please choose the item and quantity needed: [iphorm id=”2″ name=”Order Form 1″]
InspireMD specializes in embolic protection technologies to treat vascular disease and enhance patient outcomes.
InspireMD has priced a $37.5 million underwritten public offering of its common stock. The company follows through on its previously announced plans to raise capital through this equity sale. No further details on allocation or use of funds are provided in the announcement.
InspireMD receives FDA approval for its **CGuard Prime TransCarotid Stent System**, expanding its market reach for **TransCarotid Artery Revascularization (TCAR) procedures**. The approval enables access to over **35,000 annual TCAR procedures** in the U.S., backed by data from the **CGUARDIANS II pivotal trial**. The move doubles the platform’s total addressable market in the country.
InspireMD initiates a proposed public offering of its common stock alongside warrants. The company seeks to raise capital through this financial transaction, marking a potential milestone in its growth strategy.
InspireMD secures FDA approval for **CGuard Prime**, a device used in **Transcarotid Arterial Revascularization (TCAR) procedures**. The company projects this approval will roughly double its U.S. market reach by expanding treatment options for carotid artery disease. Financial results for Q3 2026 are now available, though specific metrics are not detailed in the announcement.
InspireMD adjusts its Series J and Series K warrants to tie the trigger event to the anticipated FDA approval of its **CGuard Prime 80 cm** device. The amendments could unlock up to **$11 million** in gross proceeds, contingent on regulatory clearance. The company still expects approval in **Q4 2026** as previously stated.